188 related articles for article (PubMed ID: 2685687)
1. [Serum level of the tumor marker CA 125 before second-look laparatomy in primary epithelial ovarian cancer in relation to intraoperative findings].
Meden H; Rath W; Teichmann A; Kuhn W
Onkologie; 1989 Oct; 12(5):217-20. PubMed ID: 2685687
[TBL] [Abstract][Full Text] [Related]
2. [The value of preoperative diagnosis before second-look laparotomy in ovarian cancer].
Meden H; Rath W; Ohlmeyer D
Geburtshilfe Frauenheilkd; 1990 Feb; 50(2):101-5. PubMed ID: 2180783
[TBL] [Abstract][Full Text] [Related]
3. Serum CA-125 as a guideline for the timing of a second-look operation and second-line treatment in ovarian cancer.
Jäger W; Adam R; Wildt L; Lang N
Arch Gynecol Obstet; 1988; 243(2):91-9. PubMed ID: 2456743
[TBL] [Abstract][Full Text] [Related]
4. The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer.
Niloff JM; Knapp RC; Lavin PT; Malkasian GD; Berek JS; Mortel R; Whitney C; Zurawski VR; Bast RC
Am J Obstet Gynecol; 1986 Jul; 155(1):56-60. PubMed ID: 3460341
[TBL] [Abstract][Full Text] [Related]
5. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
Xu FJ; Yu YH; Daly L; DeSombre K; Anselmino L; Hass GM; Berchuck A; Soper JT; Clarke-Pearson DL; Boyer C
J Clin Oncol; 1993 Aug; 11(8):1506-10. PubMed ID: 8336189
[TBL] [Abstract][Full Text] [Related]
6. The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer.
Gallion HH; Hunter JE; van Nagell JR; Averette HE; Cain JM; Copeland LJ; Higgins RV; Husseinzadeh N; Nahhas WA; Partridge EE
Gynecol Oncol; 1992 Jul; 46(1):29-32. PubMed ID: 1634137
[TBL] [Abstract][Full Text] [Related]
7. How to interpret serum CA 125 levels in patients with serosal involvement? A clinical dilemma.
Sevinc A; Camci C; Turk HM; Buyukberber S
Oncology; 2003; 65(1):1-6. PubMed ID: 12837976
[TBL] [Abstract][Full Text] [Related]
8. Alpha 1-acid glucoprotein in ovarian cancer with a reference to immunosuppressive acidic protein and cancer antigen 125.
Mogensen O; Mogensen B; Jakobsen A
Cancer; 1989 Nov; 64(9):1867-71. PubMed ID: 2477138
[TBL] [Abstract][Full Text] [Related]
9. CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer.
Makar AP; Kristensen GB; Børmer OP; Tropé CG
Gynecol Oncol; 1992 Jun; 45(3):323-8. PubMed ID: 1612511
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of the CA 125 assay in monitoring of ovarian cancer patients.
Hising C; Anjegård IM; Einhorn N
Am J Clin Oncol; 1991 Apr; 14(2):111-4. PubMed ID: 2028919
[TBL] [Abstract][Full Text] [Related]
11. Prediction of the presence of ovarian cancer at surgery by an immunochemical panel: CA 125 and copper-to-zinc ratio.
Gal D; Lischinsky S; Friedman M; Zinder O
Gynecol Oncol; 1989 Nov; 35(2):246-50. PubMed ID: 2680799
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors.
Lenhard MS; Nehring S; Nagel D; Mayr D; Kirschenhofer A; Hertlein L; Friese K; Stieber P; Burges A
Clin Chem Lab Med; 2009; 47(5):537-42. PubMed ID: 19317653
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer.
Niloff JM; Bast RC; Schaetzl EM; Knapp RC
Am J Obstet Gynecol; 1985 Apr; 151(7):981-6. PubMed ID: 3157319
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of CA 125 and histological findings at second-look laparotomy in ovarian carcinoma.
Meier W; Stieber P; Eiermann W; Schneider A; Fateh-Moghadam A; Hepp H
Gynecol Oncol; 1989 Oct; 35(1):44-6. PubMed ID: 2792900
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of determination of CA-125 in monitoring patients with ovarian carcinoma.
Kamińska JA; Kowalska MM; Sablińska B; Pietrzak P
Eur J Gynaecol Oncol; 1993; 14 Suppl():128-32. PubMed ID: 8200363
[TBL] [Abstract][Full Text] [Related]
16. Use of CA 125 to monitor patients with ovarian epithelial carcinomas.
Podczaski E; Whitney C; Manetta A; Larson JE; Kirk J; Stevens CW; Lyter J; Mortel R
Gynecol Oncol; 1989 May; 33(2):193-7. PubMed ID: 2703180
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of second-look laparotomy for ovarian cancer: second-look vs. serum CA125.
Liu L; Hong W; Hou Y; Yao Z; Wu A; Wang X
Chin Med Sci J; 1991 Jun; 6(2):96-9. PubMed ID: 1804384
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing period of time between negative second-look laparotomy and ovarian carcinoma recurrence. Multicenter study in Poland.
Markowska J; Wilkoszarska J; Emerich J; Debniak J; Popiela A; Pańszczak M; Kornafel J; Rossochacka B; Fisher Z; Goluda M; Małecki P
Eur J Gynaecol Oncol; 2000; 21(2):164-7. PubMed ID: 10843477
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of serial CA 125 antigen levels in ovarian cancer evaluated by second-look laparotomy.
Khoo SK; Hurst T; Webb MJ; Dickie GJ; Kearsley JH; Mackay EV
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):765-71. PubMed ID: 3477461
[TBL] [Abstract][Full Text] [Related]
20. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?
Patsner B; Orr JW; Mann WJ; Taylor PT; Partridge E; Allmen T
Gynecol Oncol; 1990 Jun; 37(3):319-22. PubMed ID: 2190870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
